| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/04/2001 | WO2001072782A2 Immuno-reactive peptide ctl epitopes of human cytomegalovirus |
| 10/04/2001 | WO2001072781A2 Human genes and expression products |
| 10/04/2001 | WO2001072779A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| 10/04/2001 | WO2001072778A2 Method of identifying inhibitors of tie-2 |
| 10/04/2001 | WO2001072777A2 Human transcription factors |
| 10/04/2001 | WO2001072776A2 Agent and method for reducing intraocular pressure |
| 10/04/2001 | WO2001072775A2 Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer |
| 10/04/2001 | WO2001072773A2 Genes isolated from dendritic cells, gene products and methods employing the same |
| 10/04/2001 | WO2001072771A2 Insulin and igf-1 receptor agonists and antagonists |
| 10/04/2001 | WO2001072770A1 Insulin potentiating peptides |
| 10/04/2001 | WO2001072765A1 ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING |
| 10/04/2001 | WO2001072701A1 Ceramide derivatives and method of use |
| 10/04/2001 | WO2001072699A1 Inhibition of angiogenesis and tumor growth |
| 10/04/2001 | WO2001072347A1 Agents promoting the formation of skin basement membrane, agents promoting the formation of artificial skin and process for producing artificial skin |
| 10/04/2001 | WO2001072341A2 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation |
| 10/04/2001 | WO2001072336A1 Compounds for targeting |
| 10/04/2001 | WO2001072335A2 Methods for effecting neuroprotection using a potassium channel modulator |
| 10/04/2001 | WO2001072333A1 Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2 |
| 10/04/2001 | WO2001072330A2 Method for immunostimulation using binding agents for the fc rec eptor of immunoglobulin a and for cancer cells or infections antigen |
| 10/04/2001 | WO2001072328A2 Methods of treating diseases with activated protein c |
| 10/04/2001 | WO2001072327A2 Use of analogues of superoxide dismutase for treating hepatocellular insufficiencies |
| 10/04/2001 | WO2001072326A1 Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases |
| 10/04/2001 | WO2001072325A1 Methods of blocking tissue destruction by autoreactive t cells |
| 10/04/2001 | WO2001072324A1 Lactams as inhibitors of a-beta protein production |
| 10/04/2001 | WO2001072323A2 Use of insulin for the treatment of cartilagenous disorders |
| 10/04/2001 | WO2001072322A2 High dosage parenteral administration of lactoferrin |
| 10/04/2001 | WO2001072321A1 η-SECRETASE-LIKE PROTEASE INHIBITORS |
| 10/04/2001 | WO2001072320A1 A method of treatment of metabolic disorders and agents useful for same |
| 10/04/2001 | WO2001072314A1 N-cam binding inhibits proliferation of and promotes differentiation of hippocampal progenitor cells |
| 10/04/2001 | WO2001072312A1 Antiviral therapeutic composition and treatment |
| 10/04/2001 | WO2001072300A1 Uses of metal salts to stabilize taxane-based compositions |
| 10/04/2001 | WO2001072299A1 Taxane-based compositions and methods of use |
| 10/04/2001 | WO2001072298A1 Treatments for immune-mediated ear disorders |
| 10/04/2001 | WO2001072297A1 Methods for inhibiting angiogenesis and tumor growth |
| 10/04/2001 | WO2001072295A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 10/04/2001 | WO2001072294A2 Method of treating hepatitis delta viral infection |
| 10/04/2001 | WO2001072290A2 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 10/04/2001 | WO2001072279A2 Medical emulsion for lubrication and delivery of drugs |
| 10/04/2001 | WO2001072278A2 Method for administering insulin to the buccal region |
| 10/04/2001 | WO2001072138A1 Chewing gum containing sulfurated amino acid compounds |
| 10/04/2001 | WO2001072119A2 Non-human animal model for growth deficiency and information processing or cognitive function defects and use thereof |
| 10/04/2001 | WO2001044198A8 Amphiphilic quinolylpolyamines as transfer agents for biologically active macromolecules |
| 10/04/2001 | WO2001043704A8 A skin care composition that mediates cell to cell communication |
| 10/04/2001 | WO2001036638A8 Polypeptides and nucleic acids encoding same |
| 10/04/2001 | WO2001036602A3 Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same |
| 10/04/2001 | WO2001036456A3 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 10/04/2001 | WO2001023563A3 Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors |
| 10/04/2001 | WO2001023523A3 Secreted proteins and uses thereof |
| 10/04/2001 | WO2001022990A3 Methods related to immunostimulatory nucleic acid-induced interferon |
| 10/04/2001 | WO2001021773A3 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 10/04/2001 | WO2001019955A3 Lysosomal targeting pathway enzymes |
| 10/04/2001 | WO2001019828A3 Kinase inhibitors as therapeutic agents |
| 10/04/2001 | WO2001018208A3 Interferon induced polynucleotides and proteins encoded thereby |
| 10/04/2001 | WO2001016334A3 Human hydrolytic enzymes |
| 10/04/2001 | WO2001016319A3 Compositions and methods for the treatment of immune related diseases |
| 10/04/2001 | WO2001013957A3 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 10/04/2001 | WO2001012214A3 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) |
| 10/04/2001 | WO2001011047A3 Dna sequences isolated from human colonic epithelial cells |
| 10/04/2001 | WO2001007075A3 Multi-dose erythropoietin formulations |
| 10/04/2001 | WO2001000663A3 Catalytically active recombinant memapsin and methods of use thereof |
| 10/04/2001 | WO2000071564A8 Isolated nucleic acids of the p-hyde family, p-hyde proteins, and methods of inducing susceptibility to induction of cell death in cancer |
| 10/04/2001 | WO2000062795A9 UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS |
| 10/04/2001 | WO2000051632A3 COPPER AGONIST THAT BINDS ON THE COPPER BINDING SITE OF APP AND/OR EXERTS AN INHIBITING EFFECT ON THE RELEASE OF AMYLOID Aβ PEPTIDE |
| 10/04/2001 | WO2000048622A9 Method for inhibiting inflammatory responses |
| 10/04/2001 | WO2000047625A9 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 10/04/2001 | WO2000042189A9 Interleukin-20 |
| 10/04/2001 | WO2000040240A9 Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
| 10/04/2001 | WO1999055860A8 Host-encoded protein expressed on marek's disease (mdv)-infected cells and antibody thereto |
| 10/04/2001 | US20010027565 Capable of binding envelope protein of hepatitis virus; therapy and/or diagnostic tool for hepatitis infection |
| 10/04/2001 | US20010027250 Cell line derived enzyme replacement therapy for glycogen storage disease; purity; free of human immunodeficiency virus |
| 10/04/2001 | US20010027249 Chimeric antibody comprising human immunoglobin constant region and murine variable region |
| 10/04/2001 | US20010027248 Obtained from rat forebrain; characterized by binding affinity for trans-(+)-6-acetyl-4S-(4-fluorobenzolamino) -3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol; therapy and prophylaxis of neurological disorders and/or drug withdrawal |
| 10/04/2001 | US20010027247 Autoimmune diseases; inflammatory conditions; competitive binding with Human Leukocyte Antigen displacing disease-inducing endogenous peptides |
| 10/04/2001 | US20010027216 Method for preventing hormone induced adverse effects |
| 10/04/2001 | US20010027199 Administering a Tumor Necrosis Factor-alpha inhibitor from the group of metalloproteinase inhibitors, quinolones, corticoids, thalidomide, lazaroides, pentoxyphyllines, hydroxamic and carbocyclic acids; spinal disk hernias |
| 10/04/2001 | US20010027184 Serine/threonine protein kinase (H-SGK2) |
| 10/04/2001 | US20010027183 Polypeptides and polynucleotides of the thymidylate kinase family (tdk); screening for antibiotics |
| 10/04/2001 | US20010027182 Spinocerebellar ataxia type 1 (SCA1); using chaperone proteins to aid in recognition/hydrolysis of mutant ataxin-1 by the proteasome; treating Alzheimer's, Parkinson's, prion disorders, dentatorubral-pallidoluysian atrophy and SCA1 |
| 10/04/2001 | US20010027181 Treatment or prophylaxis of ischemic heart disease |
| 10/04/2001 | US20010027180 GLP-2 formulations |
| 10/04/2001 | US20010027179 Antibodies against analogs of brain-derived neurotrophic factor |
| 10/04/2001 | US20010027178 And a hydrophilic organic solvent and a surfactant; low cost, the glyceride is a good solvent for cyclosporin |
| 10/04/2001 | US20010027177 Pharmaceutical composition containing a small or medium size peptide |
| 10/04/2001 | US20010027175 Inhibiting tumor necrosis factor-alpha (TNF-a) for treating nerve conditions such as sciatica by administering antiinflammatory agent etanercept or infliximab |
| 10/04/2001 | US20010027174 Polypeptides containing neo-tryptophan; neurotensin analogs; neotryptophan derivatives; method of synthesis starting from 2-methyl-3-nitrobenzoic acid; administering to a mammal having a serotonin recognition molecule |
| 10/04/2001 | US20010026932 Agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells; may be useful as antitumor agents |
| 10/04/2001 | US20010026931 Accelerates differentiation of megakaryocytes in the presence of IL-3, and acts as a thrombopoietin, and therefore an effective medicament to various diseases involving a decrease in platelets |
| 10/04/2001 | US20010026801 Administering fusion proteins for reducing inflamation of neuronal tissues in humans; tumor necrosis factor inhibition |
| 10/04/2001 | US20010026800 Delivering an immunogen to a preselected region of the gastrointestinal tract |
| 10/04/2001 | US20010026796 TCL1 enhances Akt kinase activity and mediates its nuclear translocation |
| 10/04/2001 | US20010026794 Two heterologous DNA encoding gene products; prolonged half-life |
| 10/04/2001 | EP1138774A2 Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatement |
| 10/04/2001 | EP1138773A2 Use of plasmids for the manufacture of a composition for vaccine treatment by human and animal |
| 10/04/2001 | EP1138771A1 Coffee endo-mannanase |
| 10/04/2001 | EP1138768A2 Apoptin-associating protein AAP-5 |
| 10/04/2001 | EP1138765A1 Apoptin-associating proteins AAP-5 and AAP-6 |
| 10/04/2001 | EP1138713A2 Compounds and their manufacture and use |
| 10/04/2001 | EP1138694A1 Hirulog-like peptide |
| 10/04/2001 | EP1138692A1 Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
| 10/04/2001 | EP1137805A1 Methods of facilitating vascular growth |